SG10201912713YA - PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS - Google Patents

PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS

Info

Publication number
SG10201912713YA
SG10201912713YA SG10201912713YA SG10201912713YA SG10201912713YA SG 10201912713Y A SG10201912713Y A SG 10201912713YA SG 10201912713Y A SG10201912713Y A SG 10201912713YA SG 10201912713Y A SG10201912713Y A SG 10201912713YA SG 10201912713Y A SG10201912713Y A SG 10201912713YA
Authority
SG
Singapore
Prior art keywords
intermediates
preparing
processes
dicarboxylic acid
terminated dialkane
Prior art date
Application number
SG10201912713YA
Inventor
Carmen Oniciu
Otto Geoffroy
Original Assignee
Gemphire Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemphire Therapeutics Inc filed Critical Gemphire Therapeutics Inc
Publication of SG10201912713YA publication Critical patent/SG10201912713YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/317—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/62—Use of additives, e.g. for stabilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/63—Halogen-containing esters of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/04—Seven-membered rings not condensed with other rings
SG10201912713YA 2014-11-14 2015-11-16 PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS SG10201912713YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462079894P 2014-11-14 2014-11-14

Publications (1)

Publication Number Publication Date
SG10201912713YA true SG10201912713YA (en) 2020-02-27

Family

ID=54705886

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912713YA SG10201912713YA (en) 2014-11-14 2015-11-16 PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
SG11201702496XA SG11201702496XA (en) 2014-11-14 2015-11-16 PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201702496XA SG11201702496XA (en) 2014-11-14 2015-11-16 PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS

Country Status (14)

Country Link
US (4) US10227285B2 (en)
EP (2) EP3218349A2 (en)
JP (2) JP2017533973A (en)
KR (1) KR20170083535A (en)
CN (2) CN111704543A (en)
AU (1) AU2015346037A1 (en)
BR (1) BR112017009876A2 (en)
CA (1) CA2966631A1 (en)
HK (1) HK1244265A1 (en)
IL (1) IL252245A0 (en)
MX (1) MX2017006200A (en)
RU (1) RU2017118432A (en)
SG (2) SG10201912713YA (en)
WO (1) WO2016077832A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077832A2 (en) 2014-11-14 2016-05-19 Gemphire Therapeutics Inc. PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
WO2018165120A1 (en) * 2017-03-06 2018-09-13 Gemphire Therapeutics Inc. Effect of carboxyalkylethers on obesity symptoms and lipodystropy
CN110996928A (en) * 2017-04-18 2020-04-10 燿石治疗公司 Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof, and methods of use thereof
WO2020081837A1 (en) * 2018-10-18 2020-04-23 Gemphire Therapeutics Inc. Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
US11098002B2 (en) 2019-07-26 2021-08-24 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
US11730712B2 (en) 2021-01-25 2023-08-22 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
CA3209453A1 (en) 2021-01-25 2022-07-28 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives therof, and their use for the prevention or treatment of disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2033909A (en) 1934-12-19 1936-03-17 Niacet Chemicals Corp Manufacture of calcium levulinate
US3971816A (en) 1973-11-26 1976-07-27 Ceskoslovenska Akademie Ved Esters of carboxylic acids formally substituted by sodium or potassium in the alpha-position and the method for their preparation
DE2446753C2 (en) * 1974-10-01 1982-04-22 Deutsche Texaco Ag, 2000 Hamburg Process for the preparation of ethylenically unsaturated dicarboxylic acid dialkyl esters
CA1197242A (en) 1983-03-02 1985-11-26 Jean A. Gauthier Pyrimido¬1,2-a|pyrrolo¬2,1-c|¬1, 4|benzodiazepine-3-carboxylic acid derivatives
US4691034A (en) 1986-04-14 1987-09-01 Texaco, Inc. Purification of propylene oxide by treatment with calcium hydroxide in glycerol or sugar water
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
CA2298549C (en) 1997-07-31 2006-01-10 Kos Pharmaceuticals, Inc. Combinations of hmg-coa reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
US6239300B1 (en) 1999-02-17 2001-05-29 Phillips Petroleum Company Metallocene production process
JP2002541129A (en) 1999-04-01 2002-12-03 エスペリオン セラピューティクス インコーポレイテッド Ether compounds, compositions, and uses thereof
BR0107763A (en) * 2000-01-25 2002-11-12 Warner Lambert Co calcium dicarboxylate esters, methods for its manufacture, and treatment of vascular diseases and diabetes with the same
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US20030013660A1 (en) * 2000-10-13 2003-01-16 Shire Biochem Inc. Dioxolane analogs for improved inter-cellular delivery
US20040192771A1 (en) 2001-10-11 2004-09-30 Dasseux Jean-Louis Henri Ether compounds and compositions for cholesterol management and related uses
DE10211289A1 (en) 2002-03-14 2003-09-25 Basf Ag Combination of polyvinyl acetate from water-insoluble, acid-insoluble or alkali-insoluble polymers for the production of film coatings with very controlled release and high stability
AU2003274572A1 (en) * 2002-11-15 2004-06-15 Warner-Lambert Company Llc Method of lowering crp and reducing systemic inflammation
US7288655B2 (en) 2003-03-07 2007-10-30 Merck & Co., Inc. α v integrin receptor antagonists
WO2005002557A1 (en) 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US7345190B2 (en) * 2003-11-12 2008-03-18 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs and uses thereof
US20090208539A1 (en) 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
US8642652B2 (en) * 2005-03-17 2014-02-04 Cognis Ip Management Gmbh Cosmetic compositions containing esters based on 2-propylheptanol
FR2891459B1 (en) 2005-09-30 2007-12-28 Flamel Technologies Sa MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE INGREDIENT AND ORAL GALENIC FORM COMPRISING THE SAME
WO2007044490A2 (en) 2005-10-06 2007-04-19 Boehringer Ingelheim International Gmbh Process for making heteroaryl amine intermediate compounds
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
JP5280007B2 (en) * 2006-08-02 2013-09-04 株式会社クレハ Method for purifying hydroxycarboxylic acid, method for producing cyclic ester, and method for producing polyhydroxycarboxylic acid
WO2008018877A1 (en) * 2006-08-11 2008-02-14 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs, methods of production and uses thereof
CN101505736A (en) 2006-08-25 2009-08-12 贝林格尔.英格海姆国际有限公司 Controlled release system and method for manufacturing the same
FI20080353A0 (en) 2008-05-09 2008-05-09 Atacama Labs Oy Process for preparing a tablet with extra high drug content
EP2098250B1 (en) 2006-12-28 2016-09-28 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
WO2008124505A2 (en) 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
US7955824B2 (en) * 2007-05-11 2011-06-07 Kosan Biosciences Incorporated Methods of making epothilones
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009048938A1 (en) * 2007-10-08 2009-04-16 Keen Ingredients, Inc. Quinoa grain processing and products
CN101877971A (en) 2008-01-10 2010-11-03 赢创罗姆有限公司 Coated pharmaceutical or nutraceutical preparation with enhanced active substance release in the colon
US20090226515A1 (en) 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
FR2928925B1 (en) 2008-03-19 2011-01-07 Centre Nat Rech Scient BORON OR ALUMINUM COMPLEXES, AND USES THEREOF.
US20110064816A1 (en) 2008-05-13 2011-03-17 Dr. Reddy's Laboratories Ltd. Atorvastatin compositions
NZ589469A (en) 2008-05-20 2012-08-31 Cerenis Therapeutics Holding S A Niacin and NSAID combination for reducing niacin-induced flushing
WO2011163612A1 (en) 2010-06-24 2011-12-29 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
AU2011350396A1 (en) 2010-12-27 2013-07-11 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
HUE031004T2 (en) 2010-12-27 2017-06-28 Gemphire Therapeutics Inc Gemcabene and derivatives for treating pancreatitis
UA112539C2 (en) * 2011-03-03 2016-09-26 Новартіс Аг METHOD OF PREPARATION OF 2-CARBOXAMID-CYCLAMINE-UREINE DERIVATIVES
JP2014516080A (en) 2011-06-08 2014-07-07 エスティーアイ ファーマ， エルエルシー Water-soluble pharmaceutically active organic compound formulation with controlled absorption for once-daily administration
EP2787986B1 (en) 2011-12-08 2017-10-18 Syndromex Ltd. Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof
CN110025608A (en) 2012-01-06 2019-07-19 燿石治疗公司 The method for reducing risk of cardiovascular diseases
WO2016077832A2 (en) 2014-11-14 2016-05-19 Gemphire Therapeutics Inc. PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
CN108366957A (en) 2015-11-06 2018-08-03 燿石治疗公司 Lucky Cabbeen for treating angiocardiopathy combines
CN110996928A (en) 2017-04-18 2020-04-10 燿石治疗公司 Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof, and methods of use thereof

Also Published As

Publication number Publication date
KR20170083535A (en) 2017-07-18
US20160137584A1 (en) 2016-05-19
SG11201702496XA (en) 2017-04-27
WO2016077832A2 (en) 2016-05-19
JP6731990B2 (en) 2020-07-29
EP3653598A1 (en) 2020-05-20
BR112017009876A2 (en) 2017-12-19
CA2966631A1 (en) 2016-05-19
US10227285B2 (en) 2019-03-12
US20200048181A1 (en) 2020-02-13
CN111704543A (en) 2020-09-25
RU2017118432A3 (en) 2019-06-06
HK1244265A1 (en) 2018-09-14
JP2019048838A (en) 2019-03-28
IL252245A0 (en) 2017-07-31
CN107108442A (en) 2017-08-29
US20170158601A9 (en) 2017-06-08
RU2017118432A (en) 2018-12-14
WO2016077832A3 (en) 2016-07-07
US20180194713A1 (en) 2018-07-12
MX2017006200A (en) 2017-11-17
JP2017533973A (en) 2017-11-16
AU2015346037A1 (en) 2017-07-06
US20220402854A1 (en) 2022-12-22
EP3218349A2 (en) 2017-09-20

Similar Documents

Publication Publication Date Title
SI3094593T1 (en) Carbon micro-plant
SG11201608711RA (en) Material itq-55, method for preparation and use
HK1232247A1 (en) Printing process
GB201412018D0 (en) [Apparatus
SG10201912713YA (en) PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
ZA201605495B (en) Immunostimulatory plasmids
GB201419214D0 (en) Bearing apparatus
GB201404617D0 (en) Instant messaging
SG11201609451VA (en) Dicing sheet
GB201404615D0 (en) Instant messaging
GB201413581D0 (en) Instant messaging
GB201413512D0 (en) Instant messaging
HUE054626T2 (en) Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
RO130539B8 (en) Herbicidal composition, preparation process and use thereof
GB201413513D0 (en) Instant messaging
GB2529189B (en) Air sampling apparatus
GB201709389D0 (en) An improved airship
GB2530420B (en) Connecting apparatus, assembly & method
SG11201700015WA (en) Improved apparatus
GB201401022D0 (en) Tracheostomy tube assemblies
GB2531886B (en) Attaching apparatus
GB2531990B (en) Securing apparatus
GB201510877D0 (en) Letterbox apparatus
GB201418754D0 (en) Collar/Mac
GB201413611D0 (en) Wind-driven apparatus